• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why GLP-1 Developer Vivani Medical's Stock Is Climbing

    6/13/24 11:18:41 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $VANI alert in real time by email

    Vivani Medical, Inc. (NASDAQ:VANI) shares are trading higher Thursday after the company announced the FDA cleared the Investigational New Drug application and lifted the clinical hold on NPM-119.

    The Details:

    The FDA’s actions clear the way for the initiation of Vivani’s LIBERATE-1 Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of NPM-119, the company’s miniature, six-month GLP-1 implant in development for the treatment of type 2 diabetes.

    “Today marks a significant milestone for Vivani as we transition to a clinical-stage company with a promising drug candidate that has the potential to address medication non-adherence, which affects approximately 50% of patients with type 2 diabetes. LIBERATE-1 represents our first-in-human study of NPM-119 in type 2 diabetes patients, as well as the first clinical application of our innovative NanoPortal™ implant technology in humans,” said Adam Mendelsohn, Ph.D., Vivani’s CEO.

    Vivani shares are moving on heavy trading volume following the company’s announcement. According to data from Benzinga Pro, more than 11.7 million shares have already been traded in the session, compared to the stock’s 100-day average of less than 174,000 shares.

    Related News: Virgin Galactic’s Board Approves Reverse Stock Split: What’s Going On With The Stock?

    How To Buy VANI Stock:

    By now you're likely curious about how to participate in the market for Vivani Medical – be it to purchase shares, or even attempt to bet against the company.

    Buying shares is typically done through a brokerage account. You can find a list of possible trading platforms here. Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so.

    If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a stock can be found at this resource. Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading – either way it allows you to profit off of the share price decline.

    VANI Price Action: According to Benzinga Pro, Vivani Medical shares are up 3% at $1.68 at the time of publication Thursday.

    Image: Mohamed Hassan from Pixabay

    Get the next $VANI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VANI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VANI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Mendelsohn Aaron gifted 20,000 shares and bought $24,600 worth of shares (20,000 units at $1.23) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    12/31/25 9:00:39 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    SEC Filings

    View All

    Vivani Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Vivani Medical, Inc. (0001266806) (Filer)

    1/27/26 4:11:14 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 424B5 filed by Vivani Medical Inc.

    424B5 - Vivani Medical, Inc. (0001266806) (Filer)

    1/27/26 6:01:48 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 10-Q filed by Vivani Medical Inc.

    10-Q - Vivani Medical, Inc. (0001266806) (Filer)

    11/13/25 8:10:56 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Williams Gregg bought $1,999,999 worth of shares (1,351,351 units at $1.48) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/28/26 10:01:22 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Williams Gregg bought $1,983,334 worth of shares (1,737,765 units at $1.14) (SEC Form 4)

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/20/26 9:00:37 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 4 filed by Director Bradbury Daniel

    4 - Vivani Medical, Inc. (0001266806) (Issuer)

    1/5/26 6:50:12 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vivani Subsidiary Cortigent Presents Promising 6-Year Early Feasibility Study Results for the Orion System at NANS 2026

    Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology  Cortigent is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind The Company is also developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke ALAMEDA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that Cortigent, Inc. ("Cortigent"), its wholly-owned subsidiary developing brain implant de

    1/29/26 7:30:00 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivani Medical, Inc. Announces Closing of Common Stock Offering

    ALAMEDA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the closing of its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. Gross proceeds from the two transactions were approximately $4.5 million, before deducting fees and offering expens

    1/27/26 4:05:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Vivani Medical, Inc. Announces Pricing of Common Stock Offering

    ALAMEDA, Calif., Jan. 25, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today announced the pricing of a best efforts registered direct offering of 1,689,200 shares of its common stock at an offering price of $1.48 per share and concurrent private placement of 1,351,351 shares of its common stock at an offering price of $1.48 per share purchased by Gregg Williams, the Chairman of the Company's board of directors. The registered offering and the private placement were priced "at-the-market" under the rules and regulations of The Nasdaq Stock Market LLC

    1/25/26 11:36:27 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Leadership Updates

    Live Leadership Updates

    View All

    Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

    Company plans rapid advancement of semaglutide implant NPM-139, following positive weight loss data from an ongoing preclinical study of NPM-139 and promising results from the LIBERATE-1 Phase 1 clinical study of NPM-115 New $10M equity financing to enable accelerated development of NPM-139 while securing financial position into the second half of 2026 Vivani to spin off Cortigent, Inc., a division of the Company that develops brain implant devices to help patients recover critical body functions, as an independent publicly traded company ALAMEDA, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ:VANI) ("Vivani" or the "Company"), a biopharmaceutical company

    8/13/25 4:20:00 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Financials

    Live finance-specific insights

    View All

    Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

    Cortigent is a leading developer of brain implant devices based on precision neurostimulation technology. It is the only company to have obtained FDA approval of a device providing artificial vision for the profoundly blind Cortigent's new Orion® artificial vision system, developed to treat blindness caused by common conditions, has successfully completed a 6-year Early Feasibility Study Cortigent is developing a new medical device aimed at improving recovery of arm and hand motion in patients with paralysis due to stroke Vivani to sharpen focus on development of miniature, ultra long-acting GLP-1 implants for weight loss management and treatment of type 2 diabetes with once or twice-year

    9/17/25 8:30:00 AM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $VANI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Vivani Medical Inc. (Amendment)

    SC 13D/A - Vivani Medical, Inc. (0001266806) (Subject)

    5/1/23 8:42:07 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13D filed by Vivani Medical Inc.

    SC 13D - Vivani Medical, Inc. (0001266806) (Subject)

    4/25/23 5:28:48 PM ET
    $VANI
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care